BioSpace

AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal

There’s a party going on at DISCO Pharma’s European headquarters after the precision medicine biotech signed its second major pharma partnership of the year—first Amgen, now AbbVie.

By BioSpace

1 min read
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights